22:40 , Jun 19, 2017 |  BC Extra  |  Clinical News

Antibiotic derived from soil could address drug resistance

In a paper published in...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, international Phase III TARGET 3 trial in 636 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan met the secondary composite endpoint of a greater proportion of...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Phase III data

The double-blind, international Phase III TARGET 3 trial in about 800 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan for 2 weeks met the composite primary endpoint of a greater proportion...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Bacterial RNA polymerase (RNAP) In vitro studies identified bivalent inhibitors of RNAP that could help treat bacterial infections. Biochemical and crystallography studies...
07:00 , May 22, 2014 |  BC Innovations  |  Strategy

Antibiotic team building

The National Institute of Allergy and Infectious Diseases has awarded a 5-year, $26 million grant to a center for antibiotic development that brings together researchers from Rutgers University , The Rockefeller University and Cubist Pharmaceuticals...
08:00 , Dec 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Bacterial RNA polymerase Computational and SAR studies suggest anthranilic acid compounds could be useful for treating Gram-positive bacterial...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Rifaximin soluble solid dispersion: Phase II started

Salix disclosed in its 2Q13 earnings that in June it began a double-blind, U.S. Phase II trial to evaluate once-daily rifaximin SSD tablets for 24 weeks in about 420 patients. Patients will receive 40 or...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Phase III started

Salix began the U.S. Phase III Target 3 trial to evaluate retreatment with 550 mg oral Xifaxan given thrice daily for 2 weeks in about 800 patients with IBS-D. Following a run-in period with placebo,...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, North American Phase III TARGET 2 trial in 600 patients showed that 41% of patients treated with 550 mg oral Xifaxan thrice daily for 14 days achieved adequate relief of...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, North American Phase III TARGET 1 trial in 600 patients showed that 41% of patients treated with 550 mg oral Xifaxan thrice daily for 14 days achieved adequate relief of...